BRIEF-Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement

Reuters06-01

Fusion Pharmaceuticals Inc :

* FUSION PHARMACEUTICALS RECEIVES FINAL COURT ORDER APPROVING ARRANGEMENT

* FUSION PHARMACEUTICALS - OBTAINED FINAL ORDER FROM ONTARIO SUPERIOR COURT OF JUSTICE APPROVING PREVIOUSLY ANNOUNCED STATUTORY PLAN OF ARRANGEMENT

* FUSION PHARMACEUTICALS INC - PURSUANT TO PLAN, A WHOLLY-OWNED SUBSIDIARY OF ASTRAZENECA WILL ACQUIRE ALL ISSUED AND OUTSTANDING SHARES OF FUSION

* FUSION PHARMACEUTICALS INC - FUSION SHAREHOLDERS WILL RECEIVE US$21.00 PER SHARE IN CASH UPFRONT ON COMPLETION OF ARRANGEMENT

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2440255479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-01 05:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2440255479","market":"us","top_or_hot":-1,"title":"BRIEF-Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement","media":"Reuters","content":"<html><body><p>Fusion Pharmaceuticals Inc   :</p><p>   * FUSION PHARMACEUTICALS RECEIVES FINAL COURT ORDER APPROVING ARRANGEMENT</p><p>   * FUSION PHARMACEUTICALS -  OBTAINED FINAL ORDER FROM ONTARIO SUPERIOR COURT OF JUSTICE APPROVING PREVIOUSLY ANNOUNCED STATUTORY PLAN OF ARRANGEMENT</p><p>   * FUSION PHARMACEUTICALS INC -  PURSUANT TO PLAN, A WHOLLY-OWNED SUBSIDIARY OF ASTRAZENECA WILL ACQUIRE ALL ISSUED AND OUTSTANDING SHARES OF FUSION</p><p>   * FUSION PHARMACEUTICALS INC - FUSION SHAREHOLDERS WILL RECEIVE US$21.00 PER SHARE IN CASH UPFRONT ON COMPLETION OF ARRANGEMENT</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-01 05:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fusion Pharmaceuticals Inc   :   * FUSION PHARMACEUTICALS RECEIVES FINAL COURT ORDER APPROVING ARRANGEMENT   * FUSION PHARMACEUTICALS -  OBTAINED FINAL ORDER FROM ONTARIO SUPERIOR COURT OF JUSTICE ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FUSN","symbol_name":"Fusion Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2440255479","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440255479","pubTimestamp":1717189451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Fusion Pharmaceuticals Inc   :   * FUSION PHARMACEUTICALS RECEIVES FINAL COURT ORDER APPROVING ARRANGEMENT   * FUSION PHARMACEUTICALS -  OBTAINED FINAL ORDER FROM ONTARIO SUPERIOR COURT OF JUSTICE APPROVING PREVIOUSLY ANNOUNCED STATUTORY PLAN OF ARRANGEMENT   * FUSION PHARMACEUTICALS INC -  PURSUANT TO PLAN, A WHOLLY-OWNED SUBSIDIARY OF ASTRAZENECA WILL ACQUIRE ALL ISSUED AND OUTSTANDING SHARES OF FUSION   * FUSION PHARMACEUTICALS INC - FUSION SHAREHOLDERS WILL RECEIVE US$21.00 PER SHARE IN CASH UPFRONT ON COMPLETION OF ARRANGEMENTSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FUSN":"Fusion Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Fusion Pharmaceuticals收到批准安排的最终法院命令","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FUSN":1},"content_text":"Fusion Pharmaceuticals Inc   :   * FUSION PHARMACEUTICALS RECEIVES FINAL COURT ORDER APPROVING ARRANGEMENT   * FUSION PHARMACEUTICALS -  OBTAINED FINAL ORDER FROM ONTARIO SUPERIOR COURT OF JUSTICE APPROVING PREVIOUSLY ANNOUNCED STATUTORY PLAN OF ARRANGEMENT   * FUSION PHARMACEUTICALS INC -  PURSUANT TO PLAN, A WHOLLY-OWNED SUBSIDIARY OF ASTRAZENECA WILL ACQUIRE ALL ISSUED AND OUTSTANDING SHARES OF FUSION   * FUSION PHARMACEUTICALS INC - FUSION SHAREHOLDERS WILL RECEIVE US$21.00 PER SHARE IN CASH UPFRONT ON COMPLETION OF ARRANGEMENTSource text for Eikon:    Further company coverage:","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440255479"}